Archived This bill is from the 117th Congress (2021–2022) and is no longer under active consideration.

Bills/S. 3440117th Congress

A bill to amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

Senate: Referred

Companion bill: H.R. 6832(Identical bill)

Sponsor

Cosponsors

Introduced

2022-01-04

Last action

2022-01-04

Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

Action Timeline

Jan 4, 2022SenateLatest
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Jan 4, 2022Senate
Introduced in Senate

Official Sources

Topics